Literature DB >> 11274644

Loss of heterozygosity on chromosome arm 11q in lung carcinoids.

S Petzmann1, R Ullmann, H Klemen, H Renner, H H Popper.   

Abstract

Neuroendocrine lung tumors such as typical carcinoid, atypical carcinoid, small-cell lung carcinoma, and large-cell neuroendocrine carcinoma represent a variable group with different biologic characteristics and unclear genetical relationships. We investigated the pattern of allelic loss on chromosome arm 11q in 20 sporadic carcinoid tumors of the lung using 10 microsatellite markers. Loss of heterozygosity was found in 13 of 20 tumors. In 5 of 9 typical carcinoids, 3 distinct regions of allelic loss were identified: 11q13.1 (D11S1883), 11q14.3-11q21 (D11S906), and 11q25 (D11S910). Atypical carcinoids showed loss of heterozygosity at 4 different regions: the first, most proximal region at 11q13 between markers PYGM and D11S937; the second at 11q14.3-11q21 (D11S906); and the third and fourth defined by markers D11S939 (11q23.2-23.3) and D11S910 (11q25). However, the region 11q13 harboring the MEN1 gene was more frequently affected in atypical carcinoids (7 of 11) than in typical carcinoids (2 of 9). The high rate of allelic losses within chromosomal region 11q13 in atypical carcinoids emphasizes the importance of this region for tumor development. We also recognized that more aggressive atypical carcinoids defined by high mitotic counts, vascular invasion, and/or organ metastasis are combined with increased allelic losses. HUM PATHOL 32:333-338. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2001        PMID: 11274644     DOI: 10.1053/hupa.2001.22762

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Bronchiolar columnar cell dysplasia--genetic analysis of a novel preneoplastic lesion of peripheral lung.

Authors:  Reinhard Ullmann; Massimo Bongiovanni; Iris Halbwedl; Susanna Petzmann; Margit Gogg-Kammerer; Anna Sapino; Mauro Papotti; Gianni Bussolati; Helmut H Popper
Journal:  Virchows Arch       Date:  2003-04-09       Impact factor: 4.064

Review 2.  Neuroendocrine tumors of the thymus and mediastinum.

Authors:  Hanibal Bohnenberger; Helen Dinter; Alexander König; Philipp Ströbel
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

3.  Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome.

Authors:  Dorian R A Swarts; Sandra M H Claessen; Yvonne M H Jonkers; Robert-Jan van Suylen; Anne-Marie C Dingemans; Wouter W de Herder; Ronald R de Krijger; Egbert F Smit; Frederik B J M Thunnissen; Cornelis A Seldenrijk; Aryan Vink; Aurel Perren; Frans C S Ramaekers; Ernst-Jan M Speel
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

4.  Protein phosphatase 2A Aα regulates Aβ protein expression and stability.

Authors:  Caitlin M O'Connor; Matthew T Hoffa; Sarah E Taylor; Rita A Avelar; Goutham Narla
Journal:  J Biol Chem       Date:  2019-02-22       Impact factor: 5.157

5.  [CGH findings in neuroendocrine tumours of the lung].

Authors:  G Johnen; M Krismann; M Jaworska; K-M Müller
Journal:  Pathologe       Date:  2003-05-15       Impact factor: 1.011

6.  Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids: an array comparative genomic hybridization-based study.

Authors:  Susanna Petzmann; Reinhard Ullmann; Iris Halbwedl; Helmut H Popper
Journal:  Virchows Arch       Date:  2004-07-03       Impact factor: 4.064

7.  Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP β/ζ signaling by menin.

Authors:  Z-J Feng; S-B Gao; Y Wu; X-F Xu; X Hua; G-H Jin
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

Review 8.  Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease.

Authors:  Marta Migocka-Patrzałek; Magdalena Elias
Journal:  Cells       Date:  2021-04-13       Impact factor: 6.600

Review 9.  Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy.

Authors:  Helmut Popper; Luka Brcic
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.